Miriam Martinez Callejas from Rosewaylabs talks about LDN - Low Dose Naltrexone
Listen now
Description
Miriam Martinez Callejas is the Superintendent Pharmacist and co-founder of Roseway Labs. During her master’s degree in Pharmacy, she trained in formulating medication and her first job was in a compounding pharmacy in Spain. There, she developed a passion for helping others using her experience and knowledge of medicine. At Roseway Labs, both prescribers and patients benefit from the formulations and compounding expertise that Miriam has developed over the past 20 years. She develops new formulations, finds ways to meet complex patient needs and trains practitioners to prescribe compounded medications. In demand as a conference speaker, she has participated in many sessions including at Menopause in Aesthetics, Aesthetics Medicine Live, Integrative and Personalised Medicine Congress, LDN Conference and BAHRS. As Superintendent Pharmacist, Miriam is responsible for ensuring that Roseway Labs operates in compliance with General Pharmaceutical Council regulations pertaining to the safe and effective provision of pharmacy and compounding services. For information on LDN, go to https://linktr.ee/ldnrt Our webinars and training courses can be purchased from https://www.ldnrtevents.com/collections/webinars-and-training-courses We have a list of LDN Q&As on our website https://ldnresearchtrust.org/questions-and-answers Visit our website, which is packed with information on Low Dose Naltrexone (LDN) for Autoimmune Conditions, Cancers, Chronic Pain, Women's Health and more. https://www.ldnresearchtrust.org We have a very active FB Closed Group https://www.facebook.com/groups/LDNRT/
More Episodes
Darren from the UK talks about how difficult it was to get an MCAS Diagnosis. What treatments was he offered, and how did he find a private doctor to listen to him and prescribe LDN, among other treatments, which helped him tremendously.
Published 05/01/24
Catherine from the US share her LDN, MCAS, gastroparesis, MALS, RLS,journey and struggles with us.
Published 04/24/24